Evidence map›Paper›PMID 27796796›Full record

ReviewCurrent allergy and asthma reports2016

The Reemergence of the Asthma-COPD Overlap Syndrome: Characterizing a Syndrome in the Precision Medicine Era.

Stephanie A Christenson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current allergy and asthma reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Stephanie A ChristensonDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Department of Medicine, University of California, 513 Parnassus Ave HSE 1355A, San Francisco, CA, 94143, USA. stephanie.christenson@ucsf.edu.

Funding

UCSF Career Development Program in Omics of Lung DiseasesK12HL119997 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BURCHARD, ESTEBAN GONZALEZ, ERLE, DAVID J · 2013 to 2017
$1.4M
Identifying the Th2 endotype in COPD: clinical and pathologic implicationsK23HL123778 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTENSON, STEPHANIE A · 2015 to 2019
$847k
NHLBI NIH HHS K12 HL119997NHLBI NIH HHS K23 HL123778
6 · The paper itself

Abstract

purpose of reviewThe asthma-COPD overlap syndrome (ACOS) has reemerged in the medical literature. This review addresses our current understanding of ACOS as a clinical and biological entity and how new and existing therapies may be targeted to this group. RECENT

findingsMany studies suggest that ACOS is common and associated with more morbidity than asthma and COPD in general. However, there is no consensus on an ACOS definition, likely due to the heterogeneity of the disease. Variable definitions have led to variable results in ACOS studies. Given this clinical variability, biomarkers (e.g., eosinophils and type 2 inflammatory markers) are increasingly being used to identify an ACOS molecular phenotype which appears to be more responsive to inhaled corticosteroids. Although ACOS has become a popular diagnosis, it is unclear whether identifying ACOS as a separate disease entity is clinically useful. Future studies should focus on identifying key clinical features and biomarkers that characterize vulnerable and treatment-responsive patients.

Indexed as

Adrenal Cortex HormonesAsthmaHumansPrecision MedicinePulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesAsthma-COPD overlap syndromeEosinophilsType 2 inflammation

Identifiers

PMID27796796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.